On November 1, 2022 VCN Biosciences, a clinical–stage company developing oncolytic immuno-oncology products reported the publication of data from the Clinical Trial P-VCNA-002 conducted in patients with Pancreatic Cancer that received VCN-01 by intratumorally administration (Press release, VCN Biosciences, NOV 1, 2022, View Source [SID1234606778]). The paper appears in Peer-Reviewed Journal of Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Highlights from the article include:
➢ Treatment based in three intratumoral doses of VCN-01 is generally well-tolerated.
➢ VCN-01 treatment results in disease stabilization of injected lesions.
➢ VCN-01 is detected in blood as secondary peaks and in post-treatment tumor biopsies, indicating active virus replication.
➢ Patients present increasing levels of hyaluronidase in sera over time which confirm sustained intratumor VCN-01 replication
➢ VCN-01 decreases tumor stiffness in pancreatic patients, suggesting stromal disruption
Manel Cascalló, CEO of VCN Biosciences, said, "We are very excited to publish our clinical data obtained with VCN-01 by intratumor route in patients with pancreatic cancer. The product has demonstrated a good safety profile when combined with the standard chemotherapy for this tumor type, and we have been preliminary evidence of its capacity to control the growth of this extremely aggressive tumor. Although this trial was designed as a Proof of Concept study, it has allowed to confirm the mechanism of action of VCN-01 in the clinicals setting. We also want to thank patients and families for their willingness to participate in the clinical trial."
The publication is now available electronically at: VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects | Journal for ImmunoTherapy of Cancer (bmj.com)